The antibody response to pandemic H1N1 2009 influenza vaccine in adult organ transplant patients

Transplant International

Volumn 25, Issue 2, 2012, Pages 166-171

  Felldin, Marie ^a   Studahl, Marie ^a   Svennerholm, Bo ^a   Friman, Vanda ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

antibody response; influenza A H1N1 09 vaccination; organ transplantation

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; COUGHING; EPISTAXIS; FEMALE; FEVER; GRAFT RECIPIENT; HEADACHE; HEARING IMPAIRMENT; HEMAGGLUTINATION INHIBITION TEST; HERPES SIMPLEX; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MYALGIA; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VERTIGO;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; GLOMERULAR FILTRATION RATE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; ORGAN TRANSPLANTATION; PANDEMICS; TIME FACTORS; VACCINATION;

EID: 84856003171     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01391.x     Document Type: Article

References (24)

1. Vilchez RA, McCurry K, Dauber J, et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002; 2: 287.
2. Briggs JD, Timbury MC, Paton AM, Bell PR,. Viral infection and renal transplant rejection. Br Med J 1972; 4: 520.
3. Vistoli F, Focosi D, De Donno M, et al. Pancreas rejection after pandemic influenzavirus A(H1N1) vaccination or infection: a report of two cases. Transpl Int 2011; 24: e28.
4. Neumann G, Noda T, Kawaoka Y,. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009; 459: 931.
5. Echevarria-Zuno S, Mejia-Arangure JM, Mar-Obeso AJ, et al. Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 2009; 374: 2072.
6. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325: 197.
7. Kumar D, Michaels MG, Morris MI, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10: 521.
8. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM,. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28: 1740.
9. Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011; 52: 248.
10. Meyer S, Adam M, Schweiger B, et al. Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients. Transplantation 2011; 91: 1031.
11. Keshtkar-Jahromi M, Argani H, Rahnavardi M, et al. Antibody response to influenza immunization in kidney transplant recipients receiving either azathioprine or mycophenolate: a controlled trial. Am J Nephrol 2008; 28: 654.
12. Scharpe J, Evenepoel P, Maes B, et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant 2008; 8: 332.
13. Birdwell KA, Ikizler MR, Sannella EC, et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am J Kidney Dis 2009; 54: 112.
14. Gaeta GB, Pariani E, Amendola A, et al. Influenza vaccination in patients with cirrhosis and in liver transplant recipients. Vaccine 2009; 27: 3373.
15. Salles MJ, Sens YA, Boas LS, Machado CM,. Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs. Clin Transplant 2010; 24: E17.
16. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370: 580.
17. Rumke HC, Bayas JM, De Juanes JR, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008; 26: 2378.
18. Katerinis I, Hadaya K, Duquesnoy R, et al. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant 2011; 11: 1727.
19. De Lavallade H, Garland P, Sekine T, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 2011; 96: 307.
20. Issa NC, Marty FM, Gagne LS, et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011; 17: 434.
21. Ikonen N, Strengell M, Kinnunen L, et al. High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Euro Surveill 2010; 15: 5.
22. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360: 2605.
23. Dikow R, Eckerle I, Ksoll-Rudek D, et al. Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial. Am J Kidney Dis 2011; 57: 716.
24. Huang HH, Huang CC, Hsueh PY, Lee TJ,. Bilateral sudden deafness following H1N1 vaccination. Otolaryngol Head Neck Surg 2010; 143: 849.